Lenvatinib plus pembrolizumab for patients with previously treated select solid tumors: Results from the phase 2 LEAP‐005 study recurrent glioblastoma cohort
Cancer · 2025
DOI: 10.1002/cncr.70015 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Cancer, 2025. Verfasst von Sun Young Rha und 19 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Songdang Institute for Cancer Research, Seoul, Republic of…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Quinolines, Phenylurea Compounds, Glioblastoma. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, New Jersey, USA (MSD), Eisai Inc., Nutley, New Jersey, USA.
Abstract (Originalsprache)
Background
Patients with recurrent glioblastoma (GBM) have a poor prognosis and limited treatment options. The authors report the efficacy and safety of lenvatinib plus pembrolizumab in participants with recurrent GBM enrolled in the phase 2, multicohort LEAP‐005 study (NCT03797326).
Methods
Eligible participants had histologically confirmed GBM (World Health Organization grade IV) with disease progression since previous treatment, and one or more prior lines of therapy. Participants were enrolled regardless of tumor programmed cell death ligand 1 (PD‐L1) status and received oral lenvatinib 20 mg per day plus intravenous pembrolizumab 200 mg every 3 weeks. The dual primary end points were objective response rate (ORR; per Response Assessment in Neuro‐Oncology by blinded independent central review) and safety.
Results
A total of 101 participants were enrolled, with median (range) follow‐up of 23.7 (16.4‒46.6) months. The median (range) duration of treatment with lenvatinib plus pembrolizumab was 3.4 (0.3‒32.2) months. The ORR (95% confidence interval [CI]) was 20% (13%‒29%), with 20 participants achieving a partial response, and the median (range) duration of response was 3.7 (1.4+ to 27.6) months. Median (95% CI) progression‐free survival was 3.0 (2.7‒4.0) months and median (95% CI) overall survival was 8.6 (7.4‒10.8) months. Responses were observed regardless of PD‐L1 status. Treatment‐related adverse events occurred in 93 participants (92%; grade 3‒5, n = 41 [41%]). Two participants died due to treatment‐related adverse events (intestinal perforation and pneumonitis).
Conclusions
The combination of lenvatinib plus pembrolizumab demonstrated antitumor activity in a small subpopulation of participants with recurrent GBM as second‐line or later treatment. The safety profile was manageable.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Songdang Institute for Cancer Research, Seoul, Republic of Korea.
- Department of Oncology, Clínica Universidad de Navarra, Madrid, Spain.
- Medical Oncology Department, Alfred Hospital, Melbourne, Victoria, Australia.
- Integrated Center for Oncology, Centre René Gauducheau, Saint Herblain, France.
- Phase I Drug Development Unit, The Royal Marsden Hospital and The Institute of Cancer Research, Sutton, UK.
- Hospital General Universitario Gregorio Marañon and Universidad Complutense, Madrid, Spain.
ORCID-Profile: Sun Young Rha, Tae Min Kim, Matteo Simonelli, Andrew E Hendifar
Förderung
- Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, New Jersey, USA (MSD)
- Eisai Inc., Nutley, New Jersey, USA
Zitieren
APA
Rha, S. Y., Castanon, E., Gill, S., Senellart, H., Lopez, J., Márquez-Rodas, I., Victoria, I., Kim, T. M., Lwin, Z., Burger, M. C., Simonelli, M., Cassier, P. A., Hendifar, A. E., Ascierto, P. A., Dutcus, C., Okpara, C. E., Ghori, R., Jin, F., Groisberg, R., & Villanueva, L. (2025). Lenvatinib plus pembrolizumab for patients with previously treated select solid tumors: Results from the phase 2 LEAP‐005 study recurrent glioblastoma cohort. Cancer. https://doi.org/10.1002/cncr.70015
Vancouver
Rha SY, Castanon E, Gill S, Senellart H, Lopez J, Márquez-Rodas I, et al. Lenvatinib plus pembrolizumab for patients with previously treated select solid tumors: Results from the phase 2 LEAP‐005 study recurrent glioblastoma cohort. Cancer. 2025. doi:10.1002/cncr.70015
BibTeX
@article{Rha2025,
author = {Rha, Sun Young and Castanon, Eduardo and Gill, Sanjeev and Senellart, Helene and Lopez, Juanita and Márquez-Rodas, Iván and Victoria, Iván and Kim, Tae Min and Lwin, Zarnie and Burger, Michael C and Simonelli, Matteo and Cassier, Philippe A and Hendifar, Andrew E and Ascierto, Paolo A and Dutcus, Corina and Okpara, Chinyere E and Ghori, Razi and Jin, Fan and Groisberg, Roman and Villanueva, Luis},
title = {Lenvatinib plus pembrolizumab for patients with previously treated select solid tumors: Results from the phase 2 LEAP‐005 study recurrent glioblastoma cohort},
journal = {Cancer},
year = {2025},
doi = {10.1002/cncr.70015}
}
EUVIMED